Context

Prostatitis represents the most frequent urological diagnosis in men below 50 years of age and the third most common diagnosis among individuals beyond that age.1 Chronic prostatitis (CP) syndromes are traditionally classified as bacterial or abacterial. CP/chronic pelvic pain syndrome (CPPS) (National Institutes of Health (NIH) category III) is diagnosed when patients show signs and symptoms of prostatitis and pelvic pain without evidence of prostatic bacterial infection. Years of clinical research failed to discover a single aetiological factor for CP/CPPS. Therefore, therapy for CP/CPPS is essentially symptomatic and involves the use of antibacterial agents, α-blockers, anti-inflammatory drugs, phytotherapy and so on – alone or in combination.